Previous 10 | Next 10 |
2023-06-05 08:14:50 ET Bellerophon Therapeutic ( BLPH ) -71% announces top-line data from phase 3 REBUILD clinical trial of INOpulse® for treatment of fibrotic interstitial lung disease. Mallinckrodt MNK -18% to consider filing for bankruptcy again - WSJ. ...
Trial did not meet its primary endpoint related to the change in moderate to vigorous physical activity INOpulse® was safe and well-tolerated, consistent with the overall safety profile demonstrated in Phase 2 and other INOpulse® programs in PH-COPD and PH-Sarcoidosis Co...
2023-05-19 10:04:48 ET Gainers: Lucy Scientific Discovery ( LSDI ) +51% . Bioventus ( BVS ) +44% . Mallinckrodt ( MNK ) +28% . 180 Life Sciences ( ATNF ) +28% . Stereotaxis ( STXS ) +25% . Losers: Enveric Biosciences ( ENVB ...
2023-05-16 10:07:34 ET Gainers: Phio Pharmaceuticals ( PHIO ) +30% . Coya Therapeutics ( COYA ) +23% . Nanobiotix ( NBTX ) +12% . Savara ( SVRA ) +12% . Bellerophon Therapeutics ( BLPH ) +11% . Losers: Eloxx Pharmaceutical...
2023-05-15 17:31:26 ET Bellerophon Therapeutics press release ( NASDAQ: BLPH ): Q1 GAAP EPS of $0.27. Revenue of $5.64M. For further details see: Bellerophon Therapeutics GAAP EPS of $0.27, revenue of $5.64M
Last Patient Completed Blinded Treatment in REBUILD Phase 3 Trial for INOpulse®; Pivotal Top-line Data Expected in Mid-2023 WARREN, N.J., May 15, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a c...
WARREN, N.J., May 11, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that the last patient ...
2023-04-04 12:51:54 ET Gainers: Cardlytics ( CDLX ) +62% . Assure Holdings ( IONM ) +56% . The NFT Gaming Company ( NFTG ) +42% . Bullfrog AI Holdings ( BFRG ) +32% . Bellerophon Therapeutics ( BLPH ) +27% . Austin Gold ( A...
2023-03-31 08:42:17 ET Bellerophon Therapeutics press release ( NASDAQ: BLPH ): FY GAAP EPS of -$2.08 misses by $0.06 . As of December 31, 2022, the Company had unrestricted cash and cash equivalents of $6.9 million, compared to unrestricted cash and cash equivalents o...
Completed Enrollment in INOpulse® REBUILD Phase 3 trial; Pivotal Top-line Data Expected in Mid-2023 Signed License Agreement with Baylor BioSciences to Commercialize INOpulse® in Greater China Strengthened Balance Sheet Through $5 Million Registered Direct Offering with ...
News, Short Squeeze, Breakout and More Instantly...
Bellerophon Therapeutics Inc. Company Name:
BLPH Stock Symbol:
NASDAQ Market:
Bellerophon Therapeutics Inc. Website:
China Resources Beer (Holdings) Company Limited ADR (CRHKY) is expected to report for Q4 2023 Melco International Development Ltd. (MDEVF) is expected to report for quarter end 2023-12-31 Meridian Mining UK Societas (MRRDF) is expected to report $0 for Q4 2023 BKF Capital Group Inc (B...
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
Bellerophon Therapeutics Inc. (BLPH) is expected to report for Q3 2023